In  vitro and in  vivo anti- XXXX activity of a @entity25368 - @entity5188 hybrid.

@entity589 @entity5 @entity7465 @entity19 @entity8187 @entity11 @entity876 @entity5188 @entity50250 @entity25368 @entity994
@entity50250 are important compounds that exhibit multiple biological activities, including anti-inflammatory, antimitotic and antibacterial properties. In the present study, we have analyzed the potential anti- @entity5 activity of a @entity25368 named N9 (a hybrid @entity25368 - @entity5188 compound) using in  vitro and in  vivo experimental @entity11 models. Here, we report N9-induced inhibition of cell proliferation and also N9-induced cell death in a concentration-dependent manner in U87-MG @entity11 cells. These effects of N9 appear to be associated with its ability to inhibit the expression of cell cycle-associated proteins, and also the augmentation in the expression of the @entity994 ( @entity994 / @entity994 ) protein, a cyclin-dependent kinase inhibitor. Additionally, N9 also potentiates the production of the pro-apoptotic markers @entity589 and @entity876 via inhibition of @entity7465 . Moreover, our results show that N9 also significantly enhanced apoptosis of U87-MG cells with disruption of mitochondrial membrane potential, generation of ROS and @entity8187 activation. In  vivo experiments carried out in a @entity19 xenograft model of U87-MG revealed that N9 produced a significant reduction of @entity5 volume when compared to vehicle treated @entity19 . Collectively, data demonstrate that N9 possess in  vitro and in  vivo anti- @entity5 activity, an effect that seems to involve the induction of @entity876 and @entity994 proteins, as well as, the activation of mitochondrial apoptosis pathway associated with the inhibition of protein @entity7465 . Overall, this study suggests N9 is affecting a variety of intracellular pathways related to @entity5 apoptosis. Perhaps N9 or derivate molecules could represent new potential drugs for @entity5 therapeutics.
